Despite a lack of high-level evidence to support improved skin and scar quality, interest in autologous fat grafting for such continues to grow. This multi-center, double-blinded, randomized, placebo-controlled trial aimed to evaluate the effect of autologous fat grafting in patients with cutaneous scars.
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Composite-Mediated Angiogenesis for Soft Tissue Regeneration in a Large
Existing options for soft tissue restoration have significant drawbacks: autologous flaps cause donor-site defects; prosthetics are prone to foreign-body response; and fat grafting and dermal fillers are limited to small volume defects and provide transient volume restoration. To address these limitations, we developed a nanofiber-hydrogel composite to promote angiogenesis and cellular infiltration for soft-tissue regeneration, specifically in a large defect.
METHODS:
We have developed a novel composite scaffold resembling the architecture and mechanical properties of adipose tissue by interfacial bonding of biodegradable poly (caprolactone) fibers with hyaluronic acid. To examine the superior ability of our composite for soft tissue regeneration, we aim to create a large soft tissue defect model within the inguinal fat pads of female New Zealand White rabbits. Histology, immunohistochemistry, and bromodeoxyuridine (BrdU) assay were performed to investigate the ability of our composite to regenerate soft tissue in this large defect model.
RESULTS:
We previously demonstrated robust angiogenesis and host cell infiltration within our composite after subcutaneous injection into Lewis rats. We successfully developed a large soft tissue defect model by designing standardized lesions in the rabbit inguinal fat pad. At post-operation day (POD) 7, we found that a large number of macrophages infiltrated our composite, many of which were polarized toward the M2 or "pro-healing" macrophage phenotypes; such macrophages could promote the vascular ingrowth at later timepoints. Now, using our novel inguinal fat pad model, we are testing the long-term effects of our composite for soft tissue regeneration.
CONCLUSION:
We have demonstrated that our composite can facilitate blood vessel ingrowth and cellular infiltration 1 week after injection into a large soft tissue defect. Our nanofiber hydrogel composite represents a potential solution for soft-tissue reconstruction in the setting of acquired or congenital soft-tissue defects obviating the need for donor site morbidity.
PURPOSE:
Over the past century, the average life span has increased by nearly 30%, leading to an overall aging population and an increase in degenerative diseases, including osteoarthritis. Due to a lack of vasculature and low cellularity in articular cartilage, regeneration does not occur. Since we have identified three human chondroprogenitor (CP) populations, we have the ability to functionally characterize these CPs to identify if these populations give rise to unique types of cartilage.
METHODS:
Prospective FACS analysis was performed on digested fresh human bone specimens. The gating strategy was verified in vivo and in vitro. The isolated cell gene expression profile of each population was performed using q-PCR and microarray. In vitro differentiation was performed and analyzed via FACS. Cellular proliferation using CFU in vitro and EdU both in vitro and in vivo was performed. In vivo differentiation was performed using our previously published renal capsule model as well as our xenograft model. The in vivo samples were then FACS sorted for analysis and corresponding IHC (col2, col10, mmp13) and histology (safranin-o fast green and pentachrome) was performed.
RESULTS:
Three distinct populations were successfully isolated. Each cell population had a unique gene expression profile signifying a possible variance in differentiation capability. In vitro as well as in vivo differentiation varied between each population CP1-3. The relative proliferation variability also suggests inherent population differences.
CONCLUSION:
The potential to isolate a particular CP population that is most proliferative and has the capacity to give rise to articular cartilage is exciting and may provide a new therapeutic strategy for treating patients with osteoarthritis. FACS gating strategy for our three human chondroprogenitor populations, CP1-3. L. Koepke: None. 
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